$ 147.7
Key Takeaways
Risk factor
Good trading liquidity
Profitability factor
Very low or no dividends
About
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value on EV/EBI
Target Price
The average target price of KRYS is 192 and suggests 29% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
